Introduction:
The pharmaceutical industry in Italy is experiencing significant growth, with a focus on biologics imports. The demand for biologics is expected to increase in the coming years due to advancements in medical research and the aging population. In 2025, Italy imported over $10 billion worth of biologics, making it a key player in the global pharmaceutical market.
Top 20 Biologics Importers in Italy 2026:
1. Pfizer – Pfizer is a leading biologics importer in Italy, with a market share of 15%. The company’s wide range of biologic products has contributed to its success in the Italian market.
2. Roche – Roche is another major player in the biologics import market in Italy, holding a market share of 10%. The company’s innovative biologic treatments have gained popularity among healthcare providers and patients.
3. Novartis – Novartis has a market share of 8% in the biologics import market in Italy. The company’s focus on research and development has led to the introduction of several successful biologic products.
4. Sanofi – Sanofi is a key importer of biologics in Italy, with a market share of 7%. The company’s commitment to improving patient outcomes through biologic therapies has helped it maintain its position in the market.
5. AbbVie – AbbVie holds a market share of 6% in the biologics import market in Italy. The company’s portfolio of biologic treatments for various diseases has contributed to its success in the country.
6. Amgen – Amgen is a prominent biologics importer in Italy, with a market share of 5%. The company’s focus on oncology and other therapeutic areas has helped it establish a strong presence in the market.
7. Johnson & Johnson – Johnson & Johnson has a market share of 4% in the biologics import market in Italy. The company’s diverse portfolio of biologic products has made it a preferred choice among healthcare providers.
8. Merck – Merck holds a market share of 3% in the biologics import market in Italy. The company’s emphasis on innovation and quality has helped it gain traction in the competitive market.
9. Bristol-Myers Squibb – Bristol-Myers Squibb is a key player in the biologics import market in Italy, with a market share of 2%. The company’s focus on immunology and oncology has led to the successful launch of several biologic products.
10. AstraZeneca – AstraZeneca has a market share of 2% in the biologics import market in Italy. The company’s commitment to developing biologic treatments for respiratory and cardiovascular diseases has helped it carve a niche in the market.
11. Gilead Sciences – Gilead Sciences holds a market share of 1.5% in the biologics import market in Italy. The company’s innovative biologic therapies for HIV and hepatitis have positioned it as a key player in the market.
12. Biogen – Biogen is a leading biologics importer in Italy, with a market share of 1.5%. The company’s focus on neurological disorders and rare diseases has contributed to its success in the market.
13. Eli Lilly – Eli Lilly holds a market share of 1% in the biologics import market in Italy. The company’s portfolio of biologic treatments for diabetes and cancer has gained popularity among healthcare providers.
14. Takeda Pharmaceuticals – Takeda Pharmaceuticals is a key player in the biologics import market in Italy, with a market share of 1%. The company’s focus on gastroenterology and oncology has helped it establish a strong presence in the market.
15. Regeneron Pharmaceuticals – Regeneron Pharmaceuticals has a market share of 0.5% in the biologics import market in Italy. The company’s innovative biologic treatments for eye diseases and cancer have garnered attention in the market.
16. Astellas Pharma – Astellas Pharma is a prominent biologics importer in Italy, with a market share of 0.5%. The company’s focus on urology and transplantation has contributed to its success in the market.
17. Boehringer Ingelheim – Boehringer Ingelheim holds a market share of 0.5% in the biologics import market in Italy. The company’s biologic treatments for respiratory diseases and cardiovascular disorders have gained traction in the market.
18. Celgene – Celgene is a key importer of biologics in Italy, with a market share of 0.5%. The company’s focus on oncology and inflammatory diseases has helped it establish a strong presence in the market.
19. Mylan – Mylan holds a market share of 0.5% in the biologics import market in Italy. The company’s portfolio of biologic treatments for HIV and cancer has positioned it as a key player in the market.
20. Vertex Pharmaceuticals – Vertex Pharmaceuticals is a leading biologics importer in Italy, with a market share of 0.5%. The company’s focus on cystic fibrosis and other rare diseases has contributed to its success in the market.
Insights:
The biologics import market in Italy is expected to continue growing in the coming years, driven by the increasing demand for innovative treatments and advancements in medical research. With the aging population and rising prevalence of chronic diseases, biologics are becoming a preferred choice for healthcare providers and patients alike. Companies that focus on research and development, product innovation, and quality are likely to maintain a competitive edge in the market. In 2026, the biologics import market in Italy is projected to reach over $12 billion, highlighting the country’s significance in the global pharmaceutical industry.
Related Analysis: View Previous Industry Report
